After developing key methods to generate new antibodies, we continue to generate and refine human monoclonal antibodies both by adding novel functions allowing new therapeutic paradigms and developing high-throughput in vitro antibody generation to substitute animal experiments or generate new human antibodies to fight infectious pathogens, cancer and autoimmune diseases.
We partner with academia, biotech and pharma in the generation of new drugs against cancer, autoimmune diseases and infections using our antibody phage display systems, including comprehensive naïve functional human antibody gene libraries covering the world's antibody repertoire.
The control of biochemical milieu during the in vitro selection step can be employed to predetermine antibody properties at the very moment of selection, e.g. to avoid cross reactivity or generate compatible sandwich pairs. Engineering of antibodies for novel applications like intracellular protein knockdowns or allosteric switches for affinity modulation complement our human antibody generation pipelines.
Our 30+ years of experience with phage display was further employed to create creative new methods for antigen and biomarker discovery, e.g. ORFeome and Metaproteome display.
Phage display further allows for in vitro evolution to fine tune various biochemical properties, like affinity, specificity or stability of proteins, or to adapt antibody properties to various applications, like biosensors or molecular machines.
Two antibodies we made by phage display have already reached clinical evaluation.
Past or ongoing projects cover the following major topics, among others:
Animal-free generation of human antibodies by phage display for research, diagnostics and therapy
Antibodies that recognize difficult targets, conformations, small molecular differences
Discovery of antibodies against infectious pathogens, neutralizing antibodies against toxins and viruses
Improving antibody affinity and stability by in vitro evolution
Adapting antibody properties and formats to novel biosensors
Better understanding of antibody-antigen interactions, epitope, paratope and structure analysis
Antibody fusion proteins: adding completely new biochemical functions to immunoglobulins
Targeting the inside of cells: ER intrabodies and Sneaking Ligands
Synthetic biology and molecular machines: e.g. allosteric switches for antibody affinity
This is complemented by the use of our technologies for non-antibody prorteins. In particular, phage display is a powerful tool for epitope mapping, biomarker discovery or in vitro evolution, e.g.:
ORFeome Phage Display for the identification of novel therapeutic targets and biomarkers
Metraproteome Display for the study of host pathogen interactions
Tick vaccine development
Determination of minimal epitope regions of discontinuos epitopes by organism or gene specific libraries
Novel production methods for recombinant antibodies and fusion proteins, e.g. in insect cells
Protein engineering by in vitro evolution to improve various properties (affinity, stability etc.)
Close-to-product applied protein engineering projects, like the adaptation of protein properties to the requirements of non-biological engineering, e.g. particular on-chip biosensor environments
This wide spectum of basic and applied reserach topics yielded a number of technology solutions and antibodies for various successful applications - from catalog research antibodies and diagnostic kits to clinical applications against cancer or infectious diseases (more info).